These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30682900)

  • 41. Baseline Proteinuria and Serum Creatinine Concentration as Clinical Predictors of Complete Renal Response in Patients with Lupus Nephritis: A Single-Center Experience.
    Konieczny A; Kasenberg I; Mikołajczak A; Donizy P; Hałoń A; Krajewska M
    Int J Environ Res Public Health; 2022 Nov; 19(23):. PubMed ID: 36497983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proliferative lupus nephritis in the absence of overt systemic lupus erythematosus: A historical study of 12 adult patients.
    Touzot M; Terrier CS; Faguer S; Masson I; François H; Couzi L; Hummel A; Quellard N; Touchard G; Jourde-Chiche N; Goujon JM; Daugas E;
    Medicine (Baltimore); 2017 Dec; 96(48):e9017. PubMed ID: 29310419
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
    Zen M; Fuzzi E; Loredo Martinez M; Depascale R; Fredi M; Gatto M; Larosa M; Saccon F; Iaccarino L; Doria A
    Rheumatology (Oxford); 2022 Feb; 61(2):688-695. PubMed ID: 33909900
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Presentation and Treatment Outcomes of 100 Lupus Nephritis Patients: Single Center Study.
    Faroque MO; Hadiuzzaman KM; Islam SF; Hossain RM; Islam MN; Ahmed AH; Ahmed PI; Alam MR
    Mymensingh Med J; 2016 Apr; 25(2):308-15. PubMed ID: 27277365
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained remission of lupus nephritis.
    Barber CE; Geldenhuys L; Hanly JG
    Lupus; 2006; 15(2):94-101. PubMed ID: 16539280
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteinuria and serum creatinine after 12 months of treatment for lupus nephritis as predictors of long-term renal outcome: a case-control study.
    Braga FNHF; das Chagas Medeiros MM; Junior ABV; de Sousa Lima ME; Barros LCM; Pontes MX; de Sousa Lima AW; Fernandes PFCBC
    Adv Rheumatol; 2022 Jan; 62(1):2. PubMed ID: 34983697
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis.
    Hogan J; Godron A; Baudouin V; Kwon T; Harambat J; Deschênes G; Niel O
    Pediatr Nephrol; 2018 Jan; 33(1):111-116. PubMed ID: 28780657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Long-term follow-up of 101 cases with pediatric lupus nephritis in a single center in Shanghai].
    Sun L; Xu H; Liu HM; Zhou LJ; Cao Q; Shen Q; Fang XY
    Zhonghua Er Ke Za Zhi; 2011 Nov; 49(11):819-24. PubMed ID: 22336303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Analysis of associated factors for remission and relapse in proliferative and membranous lupus nephritis patients: a 4-year follow-up study].
    Qi CJ; Ye BX; Ni ZH; Cao LO; Zhang MF; Mou S; Wang Q; Yan YC; Fang W; Zhu ML; Lu RH; Qian JQ
    Zhonghua Yi Xue Za Zhi; 2013 Dec; 93(48):3826-30. PubMed ID: 24548442
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of cyclophosphamide and other immunosuppressive drugs in the treatment of patients with lupus nephritis.
    Brugos B; Sebestyen L; Tarr T; Vincze Z
    Pharmazie; 2014 Jun; 69(6):442-4. PubMed ID: 24974578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Therapeutic effect of double-filtration plasmapheresis combined with methylprednisolone to treat diffuse proliferative lupus nephritis.
    Li M; Wang Y; Qiu Q; Wei R; Gao Y; Zhang L; Wang Y; Zhang X; Chen X
    J Clin Apher; 2016 Aug; 31(4):375-80. PubMed ID: 26018932
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Predictors of renal relapse in Korean patients with lupus nephritis who achieved remission six months following induction therapy.
    Moon SJ; Park HS; Kwok SK; Ju JH; Choi BS; Park KS; Min JK; Kim HY; Park SH
    Lupus; 2013 Apr; 22(5):527-37. PubMed ID: 23423249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of Voclosporin in Proliferative Lupus Nephritis with High Levels of Proteinuria.
    Menn-Josephy H; Hodge LS; Birardi V; Leher H
    Clin J Am Soc Nephrol; 2024 Mar; 19(3):309-318. PubMed ID: 38110196
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade.
    Tse KC; Lam MF; Tang SC; Tang CS; Chan TM
    Lupus; 2007; 16(1):46-51. PubMed ID: 17283585
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of partial renal response by 12 weeks after induction therapy predicts poor renal response and systemic damage accrual in lupus nephritis class III or IV.
    Hanaoka H; Yamada H; Kiyokawa T; Iida H; Suzuki T; Yamasaki Y; Ooka S; Nagafuchi H; Okazaki T; Ichikawa D; Shirai S; Shibagaki Y; Koike J; Ozaki S
    Arthritis Res Ther; 2017 Jan; 19(1):4. PubMed ID: 28086993
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
    Tse KC; Li FK; Tang S; Tang CS; Lai KN; Chan TM
    Lupus; 2005; 14(12):947-52. PubMed ID: 16425574
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disease severity of proliferative lupus nephritis in Maghrebians.
    Tamirou F; Costedoat-Chalumeau N; Medkouri G; Daugas E; Hachulla E; Jourde-Chiche N; Karras A; le Guern V; Gnemmi V; Jadoul M; Houssiau FA
    Lupus; 2018 Jul; 27(8):1387-1392. PubMed ID: 29703123
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis.
    Radhakrishnan J; Moutzouris DA; Ginzler EM; Solomons N; Siempos II; Appel GB
    Kidney Int; 2010 Jan; 77(2):152-60. PubMed ID: 19890271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.